Trial Profile
The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by AcaDesine in Subjects Undergoing CABG).
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Acadesine (Primary)
- Indications Cardiovascular disorders; Cerebrovascular disorders; Stroke
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms RED-CABG
- Sponsors Merck Sharp & Dohme Corp.; Schering-Plough; Schering-Plough Research Institute
- 19 Jun 2019 This trial has been discontinued in France, according to European Clinical Trials Database.
- 24 May 2019 This trial is completed in Germany according to Eudra
- 21 Oct 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.